Table Graph
      published meta-analysis   sensitivity analysis   studies

CanSino (Convidecia) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias intracranial hemorrhage detailed resultsLi J, 2022 1.03 [0.02; 52.46] 1.03[0.02; 52.46]Li J, 202210%299NAnot evaluable ischemic strokedetailed resultsLi J, 2022 1.03 [0.02; 52.46] 1.03[0.02; 52.46]Li J, 202210%299NAnot evaluable Myocardial infarction detailed resultsLi J, 2022 1.03 [0.02; 52.46] 1.03[0.02; 52.46]Li J, 202210%299NAnot evaluable pulmonary embolismdetailed resultsLi J, 2022 1.03 [0.02; 52.46] 1.03[0.02; 52.46]Li J, 202210%299NAnot evaluable venous thromboembolism detailed resultsLi J, 2022 1.03 [0.02; 52.46] 1.03[0.02; 52.46]Li J, 202210%299NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-17 19:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 760 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons